3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
79
pembrolizumab
37
Bevacizumab
36
Nivolumab
33
lenvatinib
30
atezolizumab
24
durvalumab
17
Oxaliplatin
12
Ipilimumab
12
regorafenib
9
Capecitabine
9
tremelimumab
8
Injections
8
Doxorubicin
8
tislelizumab
7
sintilimab
7
Fluorouracil
7
cabozantinib
6
budigalimab
6
brivanib
6
Ramucirumab
6
toripalimab
5
Gemcitabine
5
Everolimus
5
Cyclophosphamide
5
ADI PEG20
5
fludarabine
4
Sunitinib
4
Leucovorin
4
E-7386
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Hepatocellular
×
huachansu
×
Clear all
NCT05594927
2024-08-07
BESTPOP
Beijing Shenogen Biomedical Co., Ltd
Phase 3
Recruiting
261 enrolled